Related Experiment Video
Updated: Jul 16, 2025
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
The update of treatment strategies in pediatrics with generalized pustular psoriasis in China
Yunliu Chen1, Xin Xiang1, Zhaoyang Wang1
1Department of Dermatology Beijing Children's Hospital, Capital Medical University National Center for Children's Health Beijing China.
Insights
Generalized pustular psoriasis (GPP) is a severe inflammatory skin condition. This review examines GPP genetics in Chinese patients and treatment evidence, particularly for pediatric cases, highlighting new biological agents.
Area of Science:
- Dermatology
- Genetics
- Pediatrics
Background:
- Generalized pustular psoriasis (GPP) is a severe inflammatory skin disease.
- Genetic mutations are linked to GPP and differ across ethnicities.
- Pediatric GPP data and treatment consensus in China are limited.
Purpose of the Study:
- To discuss the genetic background of GPP in Chinese patients.
- To review current treatment evidence for pediatric GPP.
- To explore the impact of biological agents on GPP management.
Main Methods:
- Literature review of genetic studies in Chinese GPP patients.
- Analysis of treatment data for pediatric GPP.
- Evaluation of evidence for systemic and biologic therapies.
Main Results:
- Genetic variations in Chinese GPP patients are identified.
- Established treatments like acitretin, methotrexate, and cyclosporine have known adverse effects in children.
- Biologic agents represent a new therapeutic avenue for GPP.
Conclusions:
- Understanding GPP genetics in China is crucial for tailored treatments.
- Careful consideration of adverse effects is necessary for conventional pediatric GPP therapies.
- Biologic therapies offer promising advancements for managing GPP in children.
Abstract:
Generalized pustular psoriasis (GPP) is a severe subtype of psoriasis, commonly combined with systemic inflammation. Gene mutations have been found to be associated with GPP and vary by ethnicity. Systemic treatments are usually required for the severity and potential complications of GPP. However, there is no common consensus in China, especially among pediatric patients, whose data are scarce. Acitretin, methotrexate, and cyclosporine are widely used in pediatrics with GPP, while the adverse effects should be highlighted. The emergence of different biological agents brings us into a new era. This article discusses the genetic background of Chinese patients and demonstrates the evidence of treatment in pediatrics with GPP.
